Raymond James reiterates Strong Buy on Ardelyx stock after court hearing

Ardelyx, Inc. (NASDAQ:ARDX) surpassed Q2 2025 expectations, reporting $97.7 million in revenue and a net loss of $0.08 per share, driven by strong sales of Ibsrela and Xphozah. This performance prompted Raymond James to raise its price target to $12.00 from $11.00, maintaining an Outperform rating. The company continues its legal challenge against CMS over Xphozah's inclusion in the Medicare Part B ESRD bundle, arguing it creates financial disincentives, with Raymond James' sales projections for Xphozah (e.g., $207M by FY28) currently not factoring in a potential favorable resolution to this dispute.

Analysis

Ardelyx, Inc. demonstrated robust operational performance in its second-quarter 2025 results, significantly surpassing analyst expectations. The company reported revenue of $97.7 million, an 18.41% beat against the $82.51 million forecast, and a narrower-than-expected net loss of $0.08 per share compared to the anticipated $0.13 loss. This outperformance was driven by stronger-than-consensus sales for its key products, Ibsrela and Xphozah, contributing to an impressive 83.9% revenue growth over the last twelve months. In response to the strong quarter, Raymond James raised its price target to $12.00 from $11.00, maintaining an Outperform rating. A significant potential catalyst for the stock is the ongoing legal challenge against CMS regarding the bundling of Xphozah. Raymond James' current sales model, which projects Xphozah revenue growing to $207 million by fiscal year 2028, does not incorporate a potential reversal of the CMS bundling decision, suggesting a favorable legal outcome could unlock material upside not currently priced into analyst forecasts.

Key Decisions for Investors

• Investors should view the strong Q2 2025 earnings beat, with revenue surprising by 18.41% and 83.9% LTM revenue growth, as validation of the company's current commercial strategy and execution.
• Closely monitor developments in the legal challenge against CMS, as a favorable ruling on Xphozah's bundling status represents a significant, unpriced upside catalyst according to Raymond James' analysis.
• Evaluate the stock's valuation in the context of Raymond James' updated $12.00 price target and its base-case sales projections, while recognizing that this valuation does not fully account for the binary risk-reward profile of the pending CMS litigation.